Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacological and clinical properties of curcumin.

Botanics : targets and therapy·2026

Same author

Validity and predictability of mid-upper arm circumference for nutrition screening in outpatient preschoolers with cerebral palsy.

Frontiers in nutrition·2025

Same author

Retinal biomarkers in cognitive impairment and dementia: Structural, functional, and molecular insights.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Dihydromyricetin attenuates age-related macular degeneration: pharmacological effects and exploration of putative targets.

Frontiers in pharmacology·2025

Same author

Biomechanical characteristics of swing techniques using different clubs in college male golfers.

PloS one·2025

Same author

Salt-templated transformation of waste plastics into single-atom catalysts for environmental and energy applications.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

The targets of curcumin.

Hongyu Zhou¹, Christopher S Beevers, Shile Huang

¹Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932, USA.

Current Drug Targets

|October 20, 2010

Summary

Curcumin, a natural compound from turmeric, exhibits anticancer, anti-inflammatory, and antioxidant properties. Its diverse molecular targets suggest potential therapeutic applications for various diseases.

Area of Science:

Natural Products Chemistry
Pharmacology
Molecular Biology

Background:

Curcumin, derived from Curcuma longa, is a polyphenol with historical medicinal use.
Recent studies highlight curcumin's potential anticancer, antiviral, anti-amyloid, antioxidant, and anti-inflammatory effects.

Purpose of the Study:

To review the pharmacological aspects of curcumin.
To elucidate the molecular mechanisms and targets of curcumin's action.
To discuss curcumin's therapeutic potential in various diseases.

Main Methods:

In vitro and in vivo studies.
Analysis of molecular targets and signaling pathways.
Literature review of pharmacological data.

More Related Videos

Enhanced Photoluminescence of Curcuma longa Extracts via Chitosan-Mediated Energy Transfer for Textile Authentication Applications

Enhanced Photoluminescence of Curcuma longa Extracts via Chitosan-Mediated Energy Transfer for Textile Authentication Applications

Published on: December 22, 2023

Related Experiment Videos

Last Updated: Jun 8, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

Enhanced Photoluminescence of Curcuma longa Extracts via Chitosan-Mediated Energy Transfer for Textile Authentication Applications

Enhanced Photoluminescence of Curcuma longa Extracts via Chitosan-Mediated Energy Transfer for Textile Authentication Applications

Published on: December 22, 2023

Main Results:

Curcumin modulates key molecular targets including transcription factors (NF-κB), growth factors (VEGF), cytokines (TNF, IL-1, IL-6), kinases (mTOR, MAPK, Akt), and enzymes (COX-2, 5-LOX).
Demonstrated efficacy in preclinical models for various diseases.
Identified diverse signaling pathways influenced by curcumin.

Conclusions:

Curcumin possesses broad therapeutic potential due to its multi-target action and safety profile.
It is a promising agent for preventing and treating malignant diseases, arthritis, allergies, Alzheimer's disease, and inflammatory conditions.
Further research into curcumin's molecular targets and pathways supports its clinical interest.